<qa>  What is the name of the subject with CD20 and CD22-positive, folli- Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have not responded or progressed after 1 or 2 prior therapies; or subjects with CD20 and CD22-positive intermediateaggressive NHL diffuse large B-cell, mantle cell, transformed follicular or follicular grade 3b NHL who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy. 